Comparison: other vs 'Placebo' (Random Effects Model) Treatment OR 95%-CI Afatinib 1.27 [0.64; 2.52] Afatinib+EGF inhibitor [0.07; 23.05] 1.31 Afatinib+HMGCR inhibitor 0.38 [0.01; 10.30] Almonertinib 2.90 [0.48; 17.69] Amivantamab + Lazertinib 3.32 [1.21; 9.11] Chemotherapy 1.38 [0.67; 2.84] Dacomitinib 0.82 [0.38; 1.78] DHFR inhibitor 1.00 [0.20; 5.08] **Erlotinib** 1.29 [0.72; 2.29] Erlotinib+chemotherapy 1.68 [0.53; 5.32] Erlotinib+COX2 inhibitor 0.41 [0.02; 10.91] Erlotinib+HER3 inhibitor 3.39 [0.65; 17.64] Erlotinib+IGF inhibitor 1.66 [0.50; 5.57] Erlotinib+MET inhibitor [0.61; 3.28] Erlotinib+MMP inhibitor 12.41 [0.62; 248.29] Erlotinib+VEGF inhibitor 1.65 [0.77; 3.52] **Furmonertinib** 1.62 [0.41; 6.45] Gefitinib [0.55; 2.38] 1.14 Gefitinib/Erlotinib 0.99 [0.32; 3.08] Gefitinib+chemotherapy 3.60 [0.33; 39.47] Gefitinib+PARP inhibitor 3.46 [0.13; 93.41] **Icotinib** 8.06 [0.38; 171.74] Lazertinib 2.35 [0.83; 6.70] Osimertinib 2.04 [0.93; 4.47] Osimertinib+chemotherapy 3.09 [0.93; 10.29] Osimertinib+VEGF inhibitor 10.72 [1.55; 74.36] Placebo 1.00 Rociletinib 2.01 [0.29; 13.77] VEGF inhibitor 6.67 [2.57; 17.30] Zorifertinib 2.68 [0.46; 15.53]


0.01

0.1


10

100

Comparison: other vs 'Placebo' (Random Effects Model)



Comparison: other vs 'Placebo' (Random Effects Model)



Comparison: other vs 'Placebo' (Random Effects Model) OR **Treatment** 95%-CI **Afatinib** 1.39 [0.62; 3.09] Afatinib+EGF inhibitor 1.31 [0.34; 5.03] 2.61 Almonertinib [0.68; 9.98] Amivantamab + Lazertinib 7.37 [2.31; 23.54] Chemotherapy 1.98 [0.95; 4.14] **Dacomitinib** 1.04 [0.47; 2.32] **DHFR** inhibitor 2.38 [0.17; 33.39] [0.62; 2.05] **Erlotinib** 1.13 Erlotinib+Autophagy inhibitor 0.25 [0.06; 1.13] Erlotinib+chemotherapy 1.25 [0.40; 3.93] Erlotinib+COX2 inhibitor 5.75 [0.22; 147.08] Erlotinib+ER inhibitor 2.95 [0.81; 10.81] Erlotinib+HER3 inhibitor 0.56 [0.08; 3.90] Erlotinib+HGF inhibitor 0.90 [0.04; 19.99] Erlotinib+IGF inhibitor 3.70 [1.19; 11.51] Erlotinib+MET inhibitor 1.10 [0.46; 2.64] Erlotinib+MMP inhibitor 0.20 [0.03; 1.34] Erlotinib+VEGF inhibitor [2.36: 9.27] 4.67 [0.57; 2.37] Gefitinib 1.16 Gefitinib/Erlotinib 0.76 [0.19; 3.00] Gefitinib+chemotherapy 1.48 [0.58; 3.78] Gefitinib+ER inhibitor 4.74 [1.36; 16.47] 13.83 [4.09; 46.85] Gefitinib+VEGF inhibitor Lazertinib 1.63 [0.61; 4.35] [0.51; 2.86] Osimertinib 1.21 Osimertinib+chemotherapy [0.51; 7.02] 1.89 9.69 [2.98; 31.50] Osimertinib+VEGF inhibitor PD-L1 inhibitor [0.03; 7.62] 0.51 Placebo 1.00 Rociletinib 0.38 [0.01; 11.24] **VEGF** inhibitor 7.73 [3.11; 19.25] 0.01 0.1

1

10

100